RU2020115758A - Созревание защитной функции слизистых оболочек и функции кишечника/легких у недоношенного ребенка - Google Patents
Созревание защитной функции слизистых оболочек и функции кишечника/легких у недоношенного ребенка Download PDFInfo
- Publication number
- RU2020115758A RU2020115758A RU2020115758A RU2020115758A RU2020115758A RU 2020115758 A RU2020115758 A RU 2020115758A RU 2020115758 A RU2020115758 A RU 2020115758A RU 2020115758 A RU2020115758 A RU 2020115758A RU 2020115758 A RU2020115758 A RU 2020115758A
- Authority
- RU
- Russia
- Prior art keywords
- antimicrobial peptide
- peptide
- use according
- antimicrobial
- seq
- Prior art date
Links
- 230000002028 premature Effects 0.000 title claims 4
- 210000004072 lung Anatomy 0.000 title claims 3
- 230000000968 intestinal effect Effects 0.000 title 1
- 210000004877 mucosa Anatomy 0.000 title 1
- 230000009993 protective function Effects 0.000 title 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 33
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 33
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 28
- 102100038326 Beta-defensin 4A Human genes 0.000 claims 6
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 206010051606 Necrotising colitis Diseases 0.000 claims 3
- 206010036590 Premature baby Diseases 0.000 claims 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 102100037437 Beta-defensin 1 Human genes 0.000 claims 2
- 102100026886 Beta-defensin 104 Human genes 0.000 claims 2
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 claims 2
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003598 Atelectasis Diseases 0.000 claims 1
- 102000000541 Defensins Human genes 0.000 claims 1
- 108010002069 Defensins Proteins 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 208000008784 apnea Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- -1 for example Proteins 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17201002 | 2017-11-10 | ||
| EP17201002.7 | 2017-11-10 | ||
| PCT/EP2018/080814 WO2019092201A2 (en) | 2017-11-10 | 2018-11-09 | Maturation of mucosal defense and gut/lung function in the preterm infant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020115758A true RU2020115758A (ru) | 2021-12-10 |
Family
ID=60301879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020115758A RU2020115758A (ru) | 2017-11-10 | 2018-11-09 | Созревание защитной функции слизистых оболочек и функции кишечника/легких у недоношенного ребенка |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200316172A1 (https=) |
| EP (1) | EP3706773A2 (https=) |
| JP (1) | JP2021502363A (https=) |
| KR (1) | KR20200095472A (https=) |
| CN (1) | CN111556759A (https=) |
| AU (1) | AU2018363783A1 (https=) |
| BR (1) | BR112020009254A2 (https=) |
| CA (1) | CA3082288A1 (https=) |
| MX (1) | MX2020004863A (https=) |
| RU (1) | RU2020115758A (https=) |
| SG (1) | SG11202003868UA (https=) |
| WO (1) | WO2019092201A2 (https=) |
| ZA (1) | ZA202002992B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019006848A (es) * | 2016-12-13 | 2019-10-07 | Defensin Therapeutics Aps | Metodos para tratar condiciones inflamatorias de los pulmones. |
| PL3713590T3 (pl) * | 2017-11-24 | 2025-09-15 | Defensin Therapeutics Aps | Ludzka beta 2 defensyna do stosowania w zapobieganiu i leczeniu choroby przeszczep przeciwko gospodarzowi |
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| CN114903973B (zh) * | 2022-04-21 | 2025-08-29 | 上海市肺科医院 | 一种呼吸道粘膜免疫增强药物组合物 |
| US20240252558A1 (en) * | 2023-01-29 | 2024-08-01 | The University Of Chicago | Probiotics to rescue maternal immune activation-induced neurodevelopment deficits |
| KR20240150943A (ko) | 2023-04-10 | 2024-10-17 | (주)인트젠 | 영유아용 유산균 프로바이오틱스 조성물 |
| CN116868958A (zh) * | 2023-09-06 | 2023-10-13 | 中国人民解放军军事科学院军事医学研究院 | 构建缺氧导致肠道应激损伤的动物模型的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| CA2502324A1 (en) * | 2002-10-14 | 2004-04-29 | Lars Thim | Glucagon - like peptide - 2 variants |
| JP2007063219A (ja) * | 2005-09-01 | 2007-03-15 | Juntendo | 新生児壊死性腸炎疾患予防剤 |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| SG172709A1 (en) * | 2008-07-18 | 2011-07-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins |
| US20110223137A1 (en) * | 2008-12-05 | 2011-09-15 | Nestec S.A. | Compositions for use in low-birth weight infants |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| JP6219277B2 (ja) * | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブＤｅｆｅｎｓｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ａｐｓ | 炎症性腸疾患の経口治療 |
| EA201200416A1 (ru) * | 2012-03-12 | 2013-09-30 | Аделя Сабир кызы Гаджиева | Способ ранней диагностики и лечения некротического энтероколита у новорожденных |
| SG11201406628RA (en) * | 2012-04-23 | 2014-11-27 | Chiesi Farma Spa | Method and system for the administration of a pulmonary surfactant by atomization |
| EP2968073B1 (en) * | 2013-03-13 | 2017-08-16 | Rush University Medical Center | Delivery device for oropharyngeal administration of mother's colostrum and milk |
| BR112018015170A2 (pt) * | 2016-01-26 | 2018-12-18 | Defensin Therapeutics Aps | métodos para tratamento de doenças, para promoção de crescimento magro, para tratamento ou normalização de uma microbiota disbiótica no intestino, para aumentar riqueza gênica da microbiota intestinal, para aumentar número de filos da microbiota intestinal, para aumentar produção de ácidos graxos de cadeia curta da microbiota intestinal/metaboloma, para aumentar número de bactérias, para diminuir número de bactérias, defensina a, defensina ss, ou um fragmento bioativo das mesmas, e, defensina a e/ou defensina ss e/ou um glp-1/análogo de glp-1. |
| MX2019006848A (es) * | 2016-12-13 | 2019-10-07 | Defensin Therapeutics Aps | Metodos para tratar condiciones inflamatorias de los pulmones. |
-
2018
- 2018-11-09 MX MX2020004863A patent/MX2020004863A/es unknown
- 2018-11-09 JP JP2020524879A patent/JP2021502363A/ja active Pending
- 2018-11-09 AU AU2018363783A patent/AU2018363783A1/en not_active Abandoned
- 2018-11-09 CA CA3082288A patent/CA3082288A1/en active Pending
- 2018-11-09 SG SG11202003868UA patent/SG11202003868UA/en unknown
- 2018-11-09 RU RU2020115758A patent/RU2020115758A/ru unknown
- 2018-11-09 EP EP18800163.0A patent/EP3706773A2/en active Pending
- 2018-11-09 KR KR1020207015411A patent/KR20200095472A/ko not_active Ceased
- 2018-11-09 BR BR112020009254-1A patent/BR112020009254A2/pt not_active IP Right Cessation
- 2018-11-09 CN CN201880085608.5A patent/CN111556759A/zh active Pending
- 2018-11-09 US US16/761,980 patent/US20200316172A1/en active Pending
- 2018-11-09 WO PCT/EP2018/080814 patent/WO2019092201A2/en not_active Ceased
-
2020
- 2020-05-21 ZA ZA2020/02992A patent/ZA202002992B/en unknown
-
2024
- 2024-06-17 US US18/745,301 patent/US20250009844A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111556759A (zh) | 2020-08-18 |
| BR112020009254A2 (pt) | 2020-10-27 |
| JP2021502363A (ja) | 2021-01-28 |
| KR20200095472A (ko) | 2020-08-10 |
| MX2020004863A (es) | 2020-10-14 |
| US20250009844A1 (en) | 2025-01-09 |
| WO2019092201A3 (en) | 2019-06-27 |
| ZA202002992B (en) | 2021-10-27 |
| CA3082288A1 (en) | 2019-05-16 |
| SG11202003868UA (en) | 2020-05-28 |
| US20200316172A1 (en) | 2020-10-08 |
| EP3706773A2 (en) | 2020-09-16 |
| WO2019092201A2 (en) | 2019-05-16 |
| AU2018363783A1 (en) | 2020-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020115758A (ru) | Созревание защитной функции слизистых оболочек и функции кишечника/легких у недоношенного ребенка | |
| JP2021502363A5 (https=) | ||
| AU2018241248B2 (en) | Treatment of respiratory infection with a TLR2 agonist | |
| JP2022500078A5 (https=) | ||
| JP2011518179A5 (https=) | ||
| CA2817787C (en) | Composition comprising a peptide and an inhibitor of viral neuraminidase | |
| Loh et al. | Noninvasive ventilation in children: a review | |
| CN115803338A (zh) | C型利尿钠肽及其治疗急性肺损伤的方法 | |
| Yokoyama et al. | Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus | |
| PE20081000A1 (es) | Nuevos analogos del peptido intestinal vasoactivo | |
| AU2009218060B2 (en) | Pharmaceutical composition for transnasal administration | |
| Kachakayala et al. | A comparative study of supraglottic airway devices Baska mask and ProSeal-laryngeal mask airway in short gynaecological procedures | |
| ES2292594T3 (es) | E-selectina para tratar o prevenir accidentes cerebrovasculares. | |
| Quezado et al. | Anesthesia and airway management of pediatric patients with Smith-Lemli-Opitz syndrome | |
| KR101901142B1 (ko) | 레빈튜브 삽입 가이더가 구비된 기관 삽관 튜브 | |
| Mukharjee et al. | Intubation of a neonate with glossopalatine ankylosis using a paraglossal approach and a laryngoscope with a straight blade | |
| Sung et al. | Bifid Epiglottis Associated with Joubert's Synd | |
| JP2025505673A (ja) | Ｃｏｖｉｄ感染症を処置するための方法および組成物 | |
| Yoshida et al. | Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study | |
| Sfera et al. | F-652 (Recombinant Human Interleukin-22) For Schizophrenia | |
| JPWO2021054448A5 (https=) | ||
| Zylicz | Fentanyl may increase breathlessness in a patient with motor neuron disease | |
| Martínez-Molina et al. | Anesthesia in a case of tracheal stenosis sequelae of COVID-19, to a tracheoplasty procedure | |
| Guzmán et al. | Secuencia de Pierre Robin | |
| CA3103164A1 (en) | Antisecretory factor for use in treatment and/or prevention of acute respiratory failure |